Clinical trials trackerPraćenje kliničkih studija

Track the trial.
Read the design.Pratite studiju.
Čitajte dizajn.

Registry-linked records make phase, population, comparator, endpoints and source visible—without turning enrollment or a press release into proof of approval.Zapisi povezani sa registrima prikazuju fazu, populaciju, komparator, ishode i izvor—bez pretvaranja upisa ili saopštenja u dokaz odobrenja.

Focused launch tracker: retatrutide late-stage programFokusirani početni pregled: kasni program retatrutida

Registry and source check: 7 September 2026Provera registara i izvora: 7. septembar 2026.
Retatrutide · Phase IIIFaza III

TRIUMPH-1

NCT05929066
Completed enrollment; results disclosedUpis završen; rezultati objavljeni
SponsorSponzor
Eli Lilly and Company
PopulationPopulacija
Adults with obesity or overweight, without diabetesOdrasli sa gojaznošću ili prekomernom težinom, bez dijabetesa
EnrollmentBroj učesnika
2,335
DurationTrajanje
About 89 weeksOko 89 nedelja
Endpoints / focusIshodi / fokus
Body-weight change; safety; OA and OSA substudiesPromena telesne mase; bezbednost; podstudije OA i OSA
ComparatorKomparator
PlaceboPlacebo
Record updatedZapis ažuriran
21 May 202621. maj 2026.
Open registry recordOtvori zapis registra
Retatrutide · Phase IIIFaza III

TRIUMPH-2

NCT05929079
Completed enrollment; topline results disclosedUpis završen; preliminarni rezultati objavljeni
SponsorSponzor
Eli Lilly and Company
PopulationPopulacija
Adults with obesity or overweight and type 2 diabetesOdrasli sa gojaznošću ili prekomernom težinom i dijabetesom tipa 2
EnrollmentBroj učesnika
1,152
DurationTrajanje
About 89 weeksOko 89 nedelja
Endpoints / focusIshodi / fokus
Body-weight and HbA1c change; safetyPromena telesne mase i HbA1c; bezbednost
ComparatorKomparator
PlaceboPlacebo
Record updatedZapis ažuriran
23 July 202623. jul 2026.
Open registry recordOtvori zapis registra
Retatrutide · Phase IIIFaza III

TRIUMPH-3

NCT05882045
Completed enrollment; topline results disclosedUpis završen; preliminarni rezultati objavljeni
SponsorSponzor
Eli Lilly and Company
PopulationPopulacija
Adults with severe obesity and established cardiovascular diseaseOdrasli sa teškom gojaznošću i utvrđenom kardiovaskularnom bolešću
EnrollmentBroj učesnika
1,946
DurationTrajanje
About 113 weeksOko 113 nedelja
Endpoints / focusIshodi / fokus
Body-weight change; safety in a high-risk populationPromena telesne mase; bezbednost u visokorizičnoj populaciji
ComparatorKomparator
PlaceboPlacebo
Record updatedZapis ažuriran
23 July 202623. jul 2026.
Open registry recordOtvori zapis registra
Retatrutide · Phase IIIFaza III

TRANSCEND-T2D-1

NCT06354660
Completed; peer-reviewed results publishedZavršena; recenzirani rezultati objavljeni
SponsorSponzor
Eli Lilly and Company
PopulationPopulacija
Adults with type 2 diabetes inadequately controlled by diet and exerciseOdrasli sa dijabetesom tipa 2 koji nije adekvatno kontrolisan ishranom i fizičkom aktivnošću
EnrollmentBroj učesnika
537
DurationTrajanje
40-week primary endpoint; about 11 months totalPrimarni ishod u 40. nedelji; ukupno oko 11 meseci
Endpoints / focusIshodi / fokus
Change in HbA1c; body weight; safetyPromena HbA1c; telesna masa; bezbednost
ComparatorKomparator
PlaceboPlacebo
Record updatedZapis ažuriran
6 June 20266. jun 2026.
Open registry recordOtvori zapis registra
Retatrutide · Phase IIIFaza III

TRANSCEND-T2D-3

NCT06297603
Enrollment complete; follow-up ongoingUpis završen; praćenje je u toku
SponsorSponzor
Eli Lilly and Company
PopulationPopulacija
Adults with type 2 diabetes and moderate or severe renal impairmentOdrasli sa dijabetesom tipa 2 i umerenim ili teškim oštećenjem bubrega
EnrollmentBroj učesnika
320
DurationTrajanje
About 14 monthsOko 14 meseci
Endpoints / focusIshodi / fokus
Glycaemic efficacy and safety with renal impairmentGlikemijska efikasnost i bezbednost uz oštećenje bubrega
ComparatorKomparator
Placebo on background therapyPlacebo uz osnovnu terapiju
Record updatedZapis ažuriran
7 September 20267. septembar 2026.
Open registry recordOtvori zapis registra
How to read statusKako čitati status

Registered, completed and published are different states.Registrovana, završena i objavljena su različita stanja.

A registry entry does not endorse a study. Completion does not guarantee publication. A topline result is not a peer-reviewed paper, and none of these states equals regulatory approval. Open the source before relying on a status.Zapis u registru ne predstavlja podršku studiji. Završetak ne garantuje publikaciju. Preliminarni rezultat nije recenzirani rad, a nijedno od tih stanja nije regulatorno odobrenje. Otvorite izvor pre oslanjanja na status.